Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Comp Eff Res ; 8(13): 1099-1110, 2019 10.
Article in English | MEDLINE | ID: mdl-31580153

ABSTRACT

Aim: To evaluate the cost-effectiveness of intravenous ferric carboxymaltose (FCM) versus placebo for the management of iron deficiency in patients with chronic heart failure in the Italian healthcare system and to estimate its impact on the national healthcare budget. Materials & methods: A Markov model was developed to project costs and health outcomes over 1 year, based on data from literature. Healthcare resources consumption was derived from an e-survey administered to clinicians. Costs were obtained from official tariffs. Results: Treatment with FCM represents a dominant strategy compared with placebo, leading to national budget annual savings of 20-97 million Euros, according to different increasing utilization rates. Conclusion: FCM is a cost-saving option for the treatment of chronic heart failure patients with iron deficiency in Italy.


Subject(s)
Anemia, Iron-Deficiency/epidemiology , Anemia, Iron-Deficiency/prevention & control , Ferric Compounds/administration & dosage , Ferric Compounds/economics , Heart Failure/epidemiology , Maltose/analogs & derivatives , Administration, Intravenous , Budgets , Chronic Disease , Cost-Benefit Analysis , Humans , Italy , Maltose/administration & dosage , Maltose/economics , Markov Chains , Models, Econometric
2.
Ital J Pediatr ; 41: 59, 2015 Aug 19.
Article in English | MEDLINE | ID: mdl-26286526

ABSTRACT

Aim of this study was to estimate the cost that is borne by the Italian National Health Service, families, and social security due to very low birth weight infants (VLBWIs) without prematurity-related morbidities up to the age of 18 months. We followed up on 150 VLBWIs and 145 comparable full-term infants (FTIs) who were born in one of 25 different neonatal intensive care units upon discharge from the hospital and at six and 18 months of age. The average length of the primary hospitalisation of the VLBWIs was 59.7 days (SD 21.6 days), with a total cost of €20,502 (SD €8409), compared with three days (SD 0.4 days) with a total cost of €907 (SD €304) for the FTIs. The total societal cost of the VLBWIs for the first 18 months of life was €58,098 (SD €21,625), while the corresponding figure for FTIs was €24,209 (SD €15,557). Among VLBWIs, both low birth weight and gestational age were correlated with the length of hospitalisation after birth (r(2) = 0.61 and r(2) = 0.57, respectively; p values < 0.0005). Our findings highlight that the existing DRGs and tariffs inadequately reflect the actual costs for Italian National Health Service.


Subject(s)
Health Care Costs , Hospitalization/economics , Infant, Very Low Birth Weight , Diagnosis-Related Groups/economics , Female , Humans , Infant , Infant, Newborn , Infant, Premature , Italy/epidemiology , Longitudinal Studies , Male , Quality of Life
3.
Neurol Sci ; 36(2): 227-34, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25109816

ABSTRACT

The study estimates the cost of multiple sclerosis (MS) in Italy quantifying the impact of the rehabilitation on cost of illness. Patients with MS were enrolled at MS clinical centres, in rehabilitation units and among members with MS of the Italian MS Society across the Italy. The MS costs were captured with a questionnaire and were estimated taking into account both healthcare and non-healthcare costs as well as the productivity losses. Mean total annual costs per patients were €37,948, increasing for different disease severity: from €22,750 at an EDSS score of 0-3 to €63,047 at an EDSS score equal to or more than 7. €3,418 was due to rehabilitation (about 26.7% of direct healthcare costs) and of these 44% was attributable to admission to rehabilitation. The multivariate analysis showed a consistent trend toward increased total cost with progressive severity of MS, with presence of relapses, while the total cost decreases with a better quality of life. The burden increases as the MS becomes more severe and with relapse occurrence, moreover we observed high costs due to admission to rehabilitation suggesting that different rehabilitation setting might be considered to reduce the financial burden and increase the quality of life for person with MS.


Subject(s)
Cost of Illness , Multiple Sclerosis/economics , Multiple Sclerosis/rehabilitation , Female , Health Expenditures/statistics & numerical data , Humans , Italy/epidemiology , Male , Middle Aged , Multiple Sclerosis/epidemiology , Multiple Sclerosis/psychology , Multivariate Analysis , Quality of Life , Severity of Illness Index , Surveys and Questionnaires
4.
Clin Drug Investig ; 32(4): 253-65, 2012 Apr 01.
Article in English | MEDLINE | ID: mdl-22352412

ABSTRACT

BACKGROUND: Asthma is a chronic disease characterized by acute symptomatic episodes with variable severity and duration. Pharmacological asthma management aims to achieve and maintain control without side effects, thus improving quality of life and reducing the economic impact. Recently, a clinical trial showed the non-inferiority of beclomethasone/formoterol (BDP/F) versus fluticasone propionate/salmeterol (FP/S) in adults with moderate to severe persistent asthma. However, this study did not provide evidence on costs and did not quantify quality-of-life parameters. OBJECTIVE: The objective of the present study was to assess the cost effectiveness and cost utility of BDP/F versus FP/S in patients with moderate to severe asthma from the perspective of the Italian National Health Service (NHS). METHODS: A Markov model (MM) was used, with five health states for the different levels of asthma control: successful control, sub-optimal control, outpatient-managed exacerbation, inpatient-managed exacerbation, and death. Model data were derived from the ICAT SE study and from expert panels. Three outcomes were considered: time spent in successful control state, costs and quality-adjusted life-years (QALYs). RESULTS: The model shows that BDP/F treatment led to a slight increase of weeks in successful control compared with FP/S, with a lower cost. The probabilistic sensitivity analysis highlights that in 64% and 68% of the Monte Carlo simulations, BDP/F outperformed FP/S in terms of weeks in successful control and QALYs. Considering the expected cost of the two strategies, in 90% of simulations BDP/F was the least expensive choice. In particular, BDP/F was cost saving as compared with FP/S in about 63% and 59% of simulations as shown by the cost-utility and cost-effectiveness analysis, respectively. CONCLUSION: Overall, from the Italian NHS perspective, BDP/F treatment is associated with a reduction in cost and offers a slight increase of effectiveness in terms of weeks spent in successful control and QALYs.


Subject(s)
Albuterol/analogs & derivatives , Androstadienes/economics , Anti-Asthmatic Agents/economics , Beclomethasone/economics , Ethanolamines/economics , Albuterol/economics , Albuterol/therapeutic use , Androstadienes/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/economics , Beclomethasone/administration & dosage , Beclomethasone/therapeutic use , Computer Simulation , Cost-Benefit Analysis , Drug Combinations , Ethanolamines/administration & dosage , Ethanolamines/therapeutic use , Fluticasone-Salmeterol Drug Combination , Formoterol Fumarate , Humans , Italy , Markov Chains , Models, Economic , Quality-Adjusted Life Years , Severity of Illness Index
5.
Health Serv Manage Res ; 24(1): 45-54, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21285365

ABSTRACT

In the mental health field, the creation of networks that can guarantee the smooth coordination of services and organizations across sectors is a priority in the policy agenda of several countries. In Italy, Departments of Mental Health (DMHs) have been designated responsible for the system of specialist mental health services, and also mandated as the conveners and leaders of interorganizational and cross-sectoral networks, by a system-wide reform. This study aims to understand how mental health networks have been assembled in this context and the factors and motivations that have shaped their scope. By combining an analysis of policies with a survey of DMH directors, we have determined that DMHs have preferentially formed collaborative relationships with social service providers (local governments) and the voluntary sector. In contrast, relationships with substance abuse and addiction services and primary care providers were weak and stifled by a lack of trust and by conflict about respective contributions to mental care. We explore the reasons for this selectivity in interorganizational relationships and propose that a lack of targeted incentives in policy guidelines, on the one hand, and the existence of a mandated network leadership, on the other, have led to a rather narrow range of collaborations.


Subject(s)
Health Policy , Mental Health Services/organization & administration , Guidelines as Topic , Health Care Reform , Health Care Surveys , Health Facility Administration , Humans , Interdepartmental Relations , Interinstitutional Relations , Italy , Mental Health Services/legislation & jurisprudence , Substance-Related Disorders/therapy
6.
Eur J Health Econ ; 10(1): 47-55, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18379831

ABSTRACT

The study determines the cost-utility of a unilateral electronic knee prosthesis (C-leg) compared to mechanical alternatives in trans-femoral amputees. For each type of prosthesis, 50 patients, treated in a major Italian centre, were enrolled. Quality adjusted life years (QALYs) were estimated from responses to EuroQol (EQ-5D). Healthcare and social costs were assessed for the estimated life cycle of the technologies (5 years). C-leg was associated with 0.09 more QALYs per patient per year (P = 0.007). For the 5-year period, the incremental cost-utility ratio of C-leg resulted in euro 35,971 per QALY from the healthcare system perspective. If non-healthcare costs and productivity losses are included, the two groups to have similar costs (euro 66,669 vs euro 66,927).


Subject(s)
Knee Prosthesis/economics , Quality-Adjusted Life Years , Robotics/economics , Adult , Amputees , Cost-Benefit Analysis , Female , Humans , Italy , Male , Middle Aged
7.
Int Arch Allergy Immunol ; 141(2): 189-98, 2006.
Article in English | MEDLINE | ID: mdl-16899987

ABSTRACT

BACKGROUND/AIMS: Up to now, few cost-of-illness (COI) studies have estimated the cost of adult asthma at an individual level on general population samples. We sought to evaluate the cost of current asthma from the societal perspective in young Italian adults and the determinants of cost variation. METHODS: In 2000, a COI study was carried out in the frame of the Italian Study on Asthma in Young Adults on 527 current asthmatics (20-44 years) screened out of 15,591 subjects from the general population in seven centres. Detailed information about direct medical expenditures (DMEs) and indirect costs due to asthma was collected at an individual level over the past 12 months. RESULTS: The mean annual cost per patient was EUR 741 (95% CI: 599-884). DMEs represented 42.8% of the total cost, whereas the remaining 57.2% was indirect costs. The largest component of DMEs was medication costs (47.3%; 23.0% was due to hospitalization). The mean annual cost per patient ranged from EUR 379 (95% CI: 216-541)for well-controlled asthmatics to EUR 1,341 (95% CI: 978-1,706) for poorly controlled cases that accounted for 46.2% of the total cost. Poor control, coexisting chronic cough and phlegm, and low socio-economic status were significantly associated with high DMEs and indirect costs. CONCLUSIONS: In Italy, asthma-related costs were substantial even in unselected patients and were largely driven by indirect costs. Since about half of the total cost was due to a limited proportion of poorly controlled asthmatics, interventions aimed at these high-cost patients could reduce the economic burden of the disease.


Subject(s)
Anti-Asthmatic Agents/economics , Asthma/economics , Asthma/epidemiology , Cost of Illness , Adolescent , Adult , Age of Onset , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Child , Cross-Sectional Studies , Direct Service Costs/statistics & numerical data , Health Expenditures , Health Resources/statistics & numerical data , Hospitalization/economics , Humans , Italy/epidemiology , Male , Middle Aged
8.
Health Policy ; 69(3): 305-15, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15276310

ABSTRACT

BACKGROUND AND PURPOSE: In a previous study we showed that compliance with evidence-based guidelines improves the health outcome of stroke patients in terms of both survival and residual disability. In this analysis, we shall investigate the impact of such guidelines on healthcare costs during the acute/sub-acute hospitalisation phase. METHOD: we considered the direct costs from the hospital's point of view, where funding is provided by the National Healthcare System. We did not consider production loss or intangible costs related to the decreased quality of life. Data was collected on both costs and guideline compliance prospectively, and the relationship between them was studied through a multivariate statistical model. RESULTS: Patients treated according to guidelines result in lower costs; on average they have a shorter length of stay in hospital (10.8 versus 12.9 days), leading to a significant difference in the consumption of hospital resources. On a level of statistical analysis, guideline compliance is a significant independent indicator of cost, together with the patient's initial disability and neurological deficit.


Subject(s)
Brain Ischemia/economics , Brain Ischemia/therapy , Guideline Adherence/economics , Hospital Costs , Practice Guidelines as Topic , Stroke/economics , Stroke/therapy , Treatment Outcome , Aged , Brain Ischemia/mortality , Cost-Benefit Analysis , Decision Support Systems, Clinical , Female , Humans , Italy/epidemiology , Male , Middle Aged , Multivariate Analysis , Proportional Hazards Models , Prospective Studies , Risk Assessment , Stroke/mortality , Survival Analysis
9.
Expert Rev Pharmacoecon Outcomes Res ; 4(5): 549-64, 2004 Oct.
Article in English | MEDLINE | ID: mdl-19807548

ABSTRACT

Different inhaled corticosteroids can be used to treat asthma but their relative efficacy on quality of life and relative economic impact are mostly unknown. A decision model compared the cost-utility of beclomethasone, beclomethasone-extrafine, fluticasone and budesonide in adult patients with either moderate or severe persistent asthma. The patients' health state was described by the Asthma Symptom Utility Index. Patients' consumption of healthcare resources, according to the health state, was elicited by a Delphi Panel. Within 2 months, beclomethasone-extrafine prolonged quality-adjusted life by 0.5-2.3 days, as compared with the other inhaled corticosteroids, and reduced asthma-related per patient costs by euro12-67.

10.
Epidemiol Psichiatr Soc ; 12(3): 175-86, 2003.
Article in Italian | MEDLINE | ID: mdl-14610853

ABSTRACT

OBJECTIVE: The objectives of the paper are the following: i) to describe the activities and the costs of care for patients with severe mental disorders; ii) to evaluate the association between costs, clients' characteristics and outcome measures. METHODS: Patients were administered the following instruments twice a year: BPRS, GAF, HoNOS, DAS II, VSSS-54, QPF. Use of psychiatric services and other resources were collected for each patient over a two-year period. RESULTS: The average yearly cost per patient is Euro 3,300. First-contact patients cost twice as much as patients already in treatment. Service costs are associated to patients' age, marital status and working condition. Annual costs are also associated with the initial score of BPRS, GAF, DAS and HoNOS. In multiple regression analysis age, initial BPRS and DAS scores, as well as being a first-contact patient, are strongly positively associated to annual costs. CONCLUSIONS: These results highlight the importance of monitoring routine activities of psychiatric services and the flow of funds for psychiatric care in the Italian public health system.


Subject(s)
Health Care Costs , Mental Disorders/economics , Mental Disorders/therapy , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Severity of Illness Index , Treatment Outcome
11.
Eur Psychiatry ; 17(8): 434-42, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12504259

ABSTRACT

This study describes service utilisation under routine clinical activity and the costs of providing mental health care for 24 months for the whole population of 330 subjects who had first contact with the Magenta Community Mental Health Centre during one year. The mean age of patients was 42.5 years, and 61% were females. According to ICD 10 criteria, 7% were diagnosed as having schizophrenia, 22% mood disorders, 37% neurotic disorders, 15% personality disorders and 19% other diagnoses. The clinical routine activity was monitored for 24 months from the first contact for each patient. The mean cost for a schizophrenic patient is more than double that of other patients. In-patient activity and community services accounted, respectively, for 49.7% and 50.3% of the total costs. Total health care costs per patient differ widely according to whether patients had been hospitalised during the observation period. Patients with a previous psychiatric contact and a longer duration of illness were more costly than the other patients. Multiple regression analysis was used to assess the association between all the individual variables and costs. For the whole population, the model explains 50% of the cost variation. Higher treatment costs were positively associated with the presence of previous psychiatric contacts and referral to the CPS by other sources than a general practitioner, and negatively associated with age.


Subject(s)
Community Mental Health Services/economics , Community Mental Health Services/statistics & numerical data , Schizophrenia/economics , Schizophrenia/therapy , Adult , Demography , Female , Health Care Costs , Humans , Italy/epidemiology , Male , Regression Analysis , Schizophrenia/epidemiology , Socioeconomic Factors , Utilization Review
12.
J Neurol ; 249(2): 152-63, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11985380

ABSTRACT

OBJECTIVES: To estimate the socio-economic impact of multiple sclerosis (MS) in Italy. METHODS: Outpatients with MS were enrolled at 44 centres across Italy. Socio-demographic, clinical and resource utilization data were collected using a validated questionnaire. Each patient completed a weekly diary of expenses due to MS over a three-month period. Direct health care costs and indirect costs (lack of productivity for the patient and for caregivers) were assessed for the whole population and were compared among five groups, categorised by disease severity (EDSS score). An analysis of variance was carried out on socio-demographic variables. RESULTS: For the total population of 566 patients, the mean direct cost over three months was ITL 2,134,000, the mean indirect cost was ITL 7,775,000. Costs were significantly higher for male patients (p < 0.05) and showed a significant increase with increasing age (p < 0.0005), disease duration (p < 0.0005) and disease severity (p < 0.0005). Costs for patients in a progressive phase were significantly higher (p < 0.0005). There were no significant geographical differences among the regions of Italy. CONCLUSIONS: This study confirms that MS represents a high economic burden, with indirect costs greatly exceeding direct costs. Unpaid caregivers remain the culturally accepted mode of care for MS patients in Italy and this study illustrates the impact of their loss of earnings. As costs increase with disease progression, these findings suggest that treatment efforts should focus on patients in the early stages of MS, in order to slow down disease progression.


Subject(s)
Health Care Costs/statistics & numerical data , Multiple Sclerosis/economics , Adolescent , Adult , Caregivers/economics , Caregivers/statistics & numerical data , Cross-Sectional Studies , Disease Progression , Economics, Pharmaceutical/statistics & numerical data , Female , Humans , Italy , Male , Middle Aged , Multiple Sclerosis/epidemiology , Patient Acceptance of Health Care/statistics & numerical data , Prospective Studies , Sex Factors , Sick Leave/economics , Sick Leave/statistics & numerical data , Socioeconomic Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...